News Center

News Center

News Center

DualityBio’s DB-1310 Granted U.S. FDA Fast Track Designation for HR+/HER2- Breast Cancer

2025-10-14

DualityBio DB-1324 HREC approval obtained and received TGA acknowledgment of the eCTN
2025-10-14

Invitation Letter | 2025 DualityBio R&D Day
2025-09-24

DualityBio’s ADAM9-Targeting ADC DB-1317 Receives FDA IND Clearance, Global Clinical Trials Initiated Simultaneously
2025-09-05

DualityBio and BioNTech Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer
2025-07-22

DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
2025-07-09

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

«
1
2
3
4
5
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai